🔴 BeyondSpring is trading 11.79% down on October 6, 2026 amid possible biotech-sector weakness

BeyondSpring is trading at $0.69, down -11.79%, with biotechnology-sector weakness a possible contributor.

• XBI was down 2.50% during the session, and market data also showed a decline in XBI on October 6.
• BeyondSpring’s FDA Fast Track and trial-funding news was announced September 29; it does not establish a cause for the October 6 decline.
• The company-specific catalyst remains unclear.